Aggressive challenging behaviour and intellectual disability.
OBJECTIVE
The aim of this article is to review reports of aggressive challenging behaviour in individuals with intellectual disability from September 2006 to March 2008.


RESULTS
Studies continued to demonstrate the prevalence and significance of aggressive challenging behaviour in persons with intellectual disability. Over half of the population engages in some form of aggression, but only a small number is responsible for frequent or severe acts. A publication that identified aggression profiles offered a promising new approach. Aggressive behaviour in adults often has multiple functions. The most frequently studied interventions were either behavioural or somatic. Parents learned skills to effectively intervene with their aggressive preschool child. Reviews of medication efficacy studies concluded that there was insufficient evidence to recommend a single medication. Psychiatrists agreed that medication should not be the first treatment option. In one study, a class of medication was found to reduce aggression, but not aggression with self-injury, or self-injury alone.


CONCLUSIONS
Research on aggressive challenging behaviour requires assessment instruments that address the topography and severity of aggression. Identifying aggression types may clarify mixed results of previous research and improve treatment effectiveness. Greater access to effective, nonmedication treatments is needed.
Benson
Betsey A
BA
Nisonger Center, Ohio State University, Columbus, Ohio 43210, USA. benson.3@osu.edu
Brooks
Whitney T
WT
D000293:Adolescent; D000328:Adult; D000374:Aggression / Q000187:drug effects / Q000523:psychology*; D001521:Behavior Therapy / Q000379:methods; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D015897:Comorbidity; D003617:Dangerous Behavior; D004493:Education; D006801:Humans; D008607:Intellectual Disability / Q000175:diagnosis* / Q000523:psychology / Q000628:therapy; D007389:Internal-External Control; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use; D018570:Risk Assessment; D012920:Social Behavior Disorders / Q000175:diagnosis* / Q000523:psychology / Q000628:therapy
D011619:Psychotropic Drugs